Chen, Y., Ren, L., Li, X., Wu, Y., Zhao, H., Feng, R., Zhang, W., Zhao, J., Yang, P., Mao, Q., Xia, H.

Background
Currently, an epidermal growth factor receptor variant III (EGFRvIII)-specific peptide (PEPvIII) vaccine has not achieved satisfactory outcomes in several clinical trials for glioblastoma. This is probably due to the poor immunogenicity of …